Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Novo Nordisk
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
Read More...
Novo Nordisk Recent News
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
Cramer suggested that the upcoming labor report could potentially trigger a buying opportunity, predicting stronger figures than expected by Wall Street.
Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk, plans to ramp up its annual investments to $7 billion by 2030.
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand
This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases.
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.
Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey
Novo Nordisk's Wegovy has been linked to greater weight loss with prolonged use, with 40% of patients still using the drug a year later. This adherence rate is three times higher than other treatments.
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Novo Nordisk has revised its full-year outlook.
Tempest Therapeutics, Microsoft, Birkenstock, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points.
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday.
Experts Weigh In On Ozempic's Evolving Side Effects And How To Handle Them
Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise
Food and beverage stocks endure their toughest week since May 2022, driven by concerns over weight-loss drugs and shifting consumer behavior.
Novo Nordisk Eyes Social Inequality To Enhance Access To Wegovy: 'Have To Be More Intentional'
Darcey Silva Accused Of Using 'Miracle' Drug Ozempic After Showing Dramatic Weight Loss
These Three New Markets May Propel Novo Nordisk's Ozempic To Greater Heights
Ozempic Competitor Wegovy Could Prevent 1.5M Heart Attacks And Strokes Over 10 Years, Study Reveals
Tracy Morgan Credits 'Miracle' Weight Loss Drug Ozempic For Shedding Pounds: 'I Ain't Letting It Go!'
Weight-Loss Drugs Ozempic, Wegovy Pose Life-Threatening Risks For Surgery And Anesthesia Patients: Expert Warns
Obesity Drug Wegovy Sales Jump 365% In H1 As Novo Nordisk Reports Solid Results, Raises FY23 Guidance
Ozempic Linked To Severe 'Roller Coaster Ride' Side Effects In Diabetic Patients
'Miracle' Weightloss Drugs Ozempic And Mounjaro Face Lawsuit Over Alleged Gastroparesis Side Effect
Shortage Of Elon Musk-Popularized 'Miracle' Weight-Loss Drug Puts Diabetic Patients In Peril, Regulator Warns
Raven-Symoné Criticizes Hollywood's Misuse Of Ozempic For 'Glamazon' Purposes: 'Save Some Medication For The People That Actually Need It'
'Ozempic Butt:' TikTok User Says 'Nothing To Brag About' After Popular Weight Loss Drug Leaves Her With Saggy Skin